Affiliation:
1. Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang,
Indonesia
2. Department of Internal Medicine, Faculty of Medicine, Pelita Harapan
University, Karawaci, Tangerang, Indonesia
Abstract
Abstract
Background Currently, the data regarding the effectiveness and safety
of tocilizumab as treatment for COVID-19 infection is still conflicting.
This study aims to give clear evidence regarding the potential benefit and
safety of tocilizumab in improving the outcome of COVID-19 patients.
Methods We systematically searched the PubMed and Europe PMC database
using specific keywords related to our aims until November 1st,
2020. All articles published on COVID-19 and tocilizumab were retrieved.
Statistical analysis was done using Review Manager 5.4 software.
Results A total of 38 studies with a total of 13 412 COVID-19
patients were included in our analysis. Our meta-analysis showed that
tocilizumab treatment is associated with reduction of mortality rate from
COVID-19 [OR 0.54 (95% CI 0.42–0.71),
p<0.00001, I
2=79%, random-effect modelling], but did not
alter the severity of COVID-19 [OR 1.05 (95% CI 0.92–1.20),
p=0.47, I
2=84%, random-effect modelling] and length of
hospital stay [Mean Difference 1.77 days (95% CI
−0.61–4.14 days), p=0.15, I
2=97%, random-effect modelling]. Tocilizumab also
does not associated with serious adverse events compared with standard of
care treatment [OR 0.91 (95% CI 0.71–1.15),
p=0.42, I
2=46%, random-effect modelling].
Conclusion Our study does not support the routine use of tocilizumab
for COVID-19 patients. Future studies should focus more on other potential
therapies for COVID-19 patients.
Subject
Drug Discovery,General Medicine
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献